Eli Lilly and Co. has acquired exclusive rights to Entos Pharmaceuticals‘ Fusogenix nucleic acid delivery technology to research, develop and commercialize nucleic acid products targeting the central and peripheral nervous system. With this technology Lilly has access to a novel delivery platform technology with the potential to solve a key delivery challenge for many nucleic acid therapeutic modalities.   Under the collaboration, Lilly and Entos have agreed to multiple programs focused ...